Frontline treatment of epithelial ovarian cancer.

about

EphA8 is a prognostic marker for epithelial ovarian cancer.Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer.

P2860

Q37190444-D054D320-BF5C-41A6-B96B-8CCB22A6CEE4 Q48721027-3A6C093A-1E12-4FDF-AE0C-1481D533C44D Q51082273-1E6FA037-BE7E-42A8-8161-3E3C221E5109

P2860

Frontline treatment of epithelial ovarian cancer.

Item

http://www.wikidata.org/entity/Q38669746

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Frontline treatment of epithelial ovarian cancer.

@en

type

Item

label

Frontline treatment of epithelial ovarian cancer.

@en

prefLabel

Frontline treatment of epithelial ovarian cancer.

@en

P1476

Frontline treatment of epithelial ovarian cancer

@en

P2093

G Raj Mohan

http://www.w3.org/2001/XMLSchema#string

Jeffrey Goh

http://www.w3.org/2001/XMLSchema#string

Rahul Ladwa

http://www.w3.org/2001/XMLSchema#string

Sally Baron-Hay

http://www.w3.org/2001/XMLSchema#string

Sumitra Ananda

http://www.w3.org/2001/XMLSchema#string

P2860

Immune Checkpoint Blockade in Cancer Therapy

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Integrated genomic analyses of ovarian carcinoma

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.

P304

1-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJCO.12449

http://www.w3.org/2001/XMLSchema#string

P478

11 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P50

Paul A Cohen

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287202606

http://www.w3.org/2001/XMLSchema#string

P698

26669253

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

Frontline treatment of epithelial ovarian cancer.

about

P2860

P2860

Frontline treatment of epithelial ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921